ClinicaliQ Trial Snapshot
- A Study of Bleximenib, Venetoclax and Azacitidine For Treatment of Participants With Newly Diagnosed Acute Myeloid Leukemia (AML) — Recruiting • Phase III • NCT06852222.
- Trial testing whether adding bleximenib to venetoclax-azacitidine improves outcomes in newly diagnosed AML with specific genetic mutations.
Verify eligibility, endpoints and current status on the original ClinicalTrials.gov registry before acting on this summary.
Use This Page For
- Quick orientation before opening the registry record.
- Checking recruitment status, phase and sponsor at a glance.
- Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying
The purpose of this study is to assess how bleximenib and Venetoclax (VEN)+ Azacitidine (AZA) works as compared to placebo and VEN+AZA alone for the treatment of participants with newly diagnosed Acute Myeloid Leukemia (AML) with a mutation in the NPM1 or KMT2A gene. Conditions: Leukemia, Myeloid, Acute Interventions: Bleximenib, Venetoclax (VEN), Azacitidine (AZA), Placebo Lead Sponsor: Janssen Research & Development, LLC Planned Enrollment: 600 participants